 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Sugemalimab combined with platinum-based chemotherapy in first-line treatment of metastatic non-small cell lung cancer

Lancet Oncol: Sugemalimab combined with platinum-based chemotherapy in first-line treatment of metastatic non-small cell lung cancer

 Last Update: 2022-03-04
 Source: Internet
 Author: User

Tags

cancer cell lines

free

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Previous studies have confirmed that PD-1 inhibitors combined with chemotherapy are effective as first-line treatment for metastatic non-small cell lung cancer (NSCLC)
.
However, there is currently no evidence that PD-L1 inhibitors combined with chemotherapy have a therapeutic effect in patients with squamous and non-squamous NSCLC

There is currently no evidence that PD-L1 inhibitors combined with chemotherapy have a therapeutic effect in patients with squamous and non-squamous NSCLC

GEMSTONE-302 is a randomized, double-blind Phase 3 clinical trial conducted in 35 hospitals and academic research centers in China to evaluate the efficacy of PD-L1 inhibitor sugemalimab in combination with chemotherapy in patients with metastatic squamous cell carcinoma.

Efficacy and safety in patients with squamous or non-squamous NSCLC

To evaluate the efficacy and safety of the PD-L1 inhibitor sugemalimab in combination with chemotherapy in patients with metastatic squamous or non-squamous NSCLC

median progression-free survival

Between December 13, 2018, and May 15, 2020, a total of 846 patients were evaluated, of whom 479 were randomized to sugelimumab (n=320) or placebo (n=159)
.
With a median follow-up of 8.

6 months as of June 8, 2020 (interim analysis), median progression-free survival was significantly longer in the sugelimumab group compared with the placebo group (7.

Median progression-free survival was significantly longer in the sugalimumab group compared to placebo The median progression-free survival was 9.

overall survival

The most common grade 3-4 treatment-related adverse events were decreased neutrophil count (sugalimab vs placebo: 33% vs 33%), decreased white blood cell count (14% vs 17%), anemia (13% vs 11%), decreased platelet count (10% vs 9%), and neutropenia (4% vs 4%)
.
Treatment-related serious adverse events were experienced by 73 (23%) and 31 (20%) patients in the sugelimab group and placebo group, respectively

some side reactions

In conclusion, compared with placebo plus chemotherapy, sugalimab plus chemotherapy significantly prolonged progression-free survival in patients with previously untreated squamous and non-squamous metastatic NSCLC, or in patients with metastatic non-small cell lung cancer New first-line treatment options for patients

Compared with placebo combined with chemotherapy, sugalimab combined with chemotherapy significantly prolongs progression-free survival in patients with previously untreated squamous and non-squamous metastatic NSCLC Choice of first-line treatment regimen compared with placebo plus chemotherapy, sugalimab plus chemotherapy significantly prolongs progression-free survival in patients with previously untreated squamous and non-squamous metastatic NSCLC, or may become a New first-line treatment options for patients with small cell lung cancer

Original source:

Caicun Zhou, et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.